Ultralife Swings to $2.4M Profit as Backlog Hits Record $136M
ULBI has more than doubled off its 52-week low of $4.9 on elevated volume (2.0× avg).
Summary
Ultralife flipped to $2.4M of net income in Q3 2026 from a $1.2M loss a year earlier, with revenue up 11.3% to $48.3M. Gross margin jumped to 27.5% from 22.2% and adjusted EBITDA more than doubled to $5.6M from $2.0M. Backlog reached $136.0M, up from $90.3M a year ago and from $117.5M at Q2 2026 — the company's highest ever. The numbers matter less for standalone valuation than as a read on the business EnerSys agreed to buy for $16.00 a share in cash, a $320M deal whose board recommendation and largest holder's 40.3% tender commitment are already on file. The stock at $15.59 sits just under the $16.00 deal price and near its 52-week high, so the market is pricing completion, not earnings. The acquisition is expected to close in Q1 2027.
At the time of this announcement, ULBI was trading at $15.59 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $260.4M. The 52-week trading range was $4.90 to $15.69. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.